Effect of verapamil on the expression of EGFR and NM23 in A549 human lung cancer cells

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 27-32

  Zhang, Chundi ^a,b   Lv, Fuzhen ^a,f   Li, Zhou ^b   Li, Xueyan ^b   Wu, Xiu Xian ^c   Hoffman, Robert M ^d,e  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

^c KAGAWA UNIVERSITY   (Japan)

^d ANTICANCER INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

EGFR; Lung cancer; nm23; Verapamil

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; NUCLEOSIDE DIPHOSPHATE KINASE NM23; VERAPAMIL;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; VERAPAMIL;

EID: 61449207399     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Zhang L, Yang Y, Wei XY, Shi YR, Liu HY, Niu RF and Hao XS: Reversing adriamycin resistance of human breast cancer cells by hyperthermia combined with interferon alpha and verapamil. J Exp Clin Cancer Res 2: 201-207, 2007.
2. Cross DJ, Flexman JA, Anzai Y, Sasaki T, Treuting PM, Maravilla KR and Minoshima S: In vivo manganese MR imaging of calcium influx in spontaneous rat pituitary adenoma. AJNR Am J Neuroradiol 28: 1865-1871, 2007.
3. Perrotton T, Trompier D, Chang XB, Di Pietro A and Baubichon-Cortay H: (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem 282: 31542-31548, 2007.
4. Rinker-Schaeffer CW, O'Keefe JP, Welch DR and Theodorescu D: Metastasis suppressor protein: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 13: 3882-3889, 2006.
5. Steeg PS, Cohn KH and Leone A: Tumor metastasis and nm23: current concept. Cancer Cells 3: 257-262, 1991.
6. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA and Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80: 200-204, 1988.
7. Wu XX, Jin XJ, Zeng Y, El Hamed AM and Kakehi Y: Low concentrations of adriamycin sensitizes human solid cancer cells to TRAIL-R2-mediated apoptosis by inducting TRAIL-R2 expression. Cancer Sci 98: 1969-1976, 2007.
8. Wu XX, Kakehi Y, Mizutani Y, Lu J, Terachi T and Ogawa O: Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 19: 19-24, 2001.
9. Durmaz R, Deliorman S and Uyar R: The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme. Clin Neurol Neurosurg 101: 238-244, 1999.
10. Weglarz L, Parfmiewicz B, Orchel A and Dzierzewicz Z: Anti-proliferative effects of inositol hexaphosphate and verapamil on human colon cancer Caco-2 and HT-29 cells. Acta Pol Pharm 5: 443-445, 2006.
11. Mayur YC, Jagadeesh S and Thimmaiah KN: Targeting calmodulin in reversing multidrug resistance in cancer cells. Mini Rev Med Chem 12: 1383-1389, 2006.
12. Ho YC, Tai KW and Chang YC: Synergistic effects of verapamil on pingyangmycin-induced cytotoxicity and apoptosis in KB cells. Oral Dis 1: 40-44, 2007.
13. de La Motte Rouge T, Valent A, Ambrosetti D, Vielh P and Lacroix L: Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Ann Pathol 27: 353-363, 2007.
14. Kijima T, Suzuki M, Ueda K, Minami S, Takeda Y, Goya S, Matsuoka H, Kumagai T, Yoshida M, Osaki T, Tachibana I, Yokota S and Kawase I: Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report. Oncol Res 16: 489-495, 2007.
15. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T and Kuwano M: Sensitivity to gefitinib (Iressa™, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3: 465-472, 2004.
16. Backer JM, Mendola CE, Kovesdi I, Fairhurst JL, O'Hara B, Eddy RL Jr, Shows TB, Mathew S, Murty VV and Chaganti RS: Chromosomal localization and nucleoside diphosphate kinase activity of human metastasis-suppressor genes NM23-1 and NM23-2. Oncogene 8: 497-502, 1993.
17. Martin KK and Pikington GJ: Nm23: An invasion suppressor gene in CNS tumors? Anticancer Res 18: 919-926, 1998.
18. MacDonald NJ, de la Rosa A and Steeg PS: The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer 31A: 1096-1100, 1995.
19. Leone A, Flatow U, King CR, Sandeen MA, Margulies IM, Liotta LA and Steeg PS: Reduced tumor incidence, metastatic potential and cytokine responsiveness of nm23-transfected melonoma cells. Cell 65: 25-35, 1991
20. Freije JM, Blay P, MacDonald NJ, Manrow RE and Steeg PS: Site-directed mutation of Nm23-H1. Mutations lacking motility suppressive capacity upon transfection are deficient in histidine-dependent protein phosphotransferase pathways in vitro. J Biol Chem 272: 5525-5532, 1997.
21. Bobe R, Yin X, Roussanne MC, Stepien O, Polidano E, Faverdin C and Marche P: Evidence for ERK1/2 activation by thrombin that is independent of EGFR transactivation. Am J Physiol Heart Circ Physiol 285: H745-754, 2003.